Global Leukemia Therapeutics Market 2016-2020

Publisher Name :
Date: 20-Sep-2016
No. of pages: 110
Inquire Before Buying

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

The analysts forecast global leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography:


  • Americas

  • APAC

  • EMEA


The report, Global Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors


  • F. Hoffmann-La Roche

  • Novartis

  • Bristol-Myers Squibb

  • AbbVie

  • Teva Pharmaceuticals


Other prominent vendors


  • Altor BioScience

  • Amgen

  • ARIAD Pharmaceuticals

  • Arno Therapeutics

  • Astex Pharmaceuticals

  • AstraZeneca

  • Baxter Healthcare

  • Bayer HealthCare

  • Bellicum Pharmaceuticals

  • Biogen

  • Boehringer Ingelheim

  • BioLineRx

  • Boston Biomedical

  • Celator Pharmaceuticals

  • Celgene

  • CTI BioPharma

  • Chroma Therapeutics

  • Chugai Pharmaceutical

  • Cyclacel Pharmaceuticals

  • Daiichi Sankyo

  • Eisai

  • Emergent BioSolutions

  • Erytech Pharma

  • Fate Therapeutics

  • Genzyme

  • Gilead Sciences

  • GlaxoSmithKline

  • iDD biotech

  • Immune Pharmaceuticals

  • Immunomedics

  • Infinity Pharmaceuticals

  • Innate Pharma

  • Jazz Pharmaceuticals

  • Juno Therapeutics

  • Karyopharm Therapeutics

  • Ligand Pharmaceuticals

  • MEDA Pharmaceuticals

  • MedImmune

  • Merck

  • Midas Pharma

  • Molecular Templates

  • MorphoSys

  • Nippon Shinyaku

  • Novo Nordisk

  • Onconova Therapeutics

  • Ono Pharmaceuticals

  • Orphan Europe

  • Otsuka

  • Pfizer

  • Portola Pharmaceuticals

  • Regeneron Pharmaceuticals

  • Sanofi

  • Sigma-Tau Pharmaceuticals

  • Stemline Therapeutics

  • Sunesis Pharmaceuticals

  • TG Therapeutics

  • TheraMAB

  • Tolero Pharmaceuticals

  • XEME Biopharma

  • Xencor

  • ZIOPHARM Oncology


Market driver


  • Technological advances in the monitoring of leukemia

  • For a full, detailed list, view our report


Market challenge


  • Limitations associated with current therapeutic options

  • For a full, detailed list, view our report


Market trend


  • Rise in the development of combination therapies

  • For a full, detailed list, view our report


Key questions answered in this report


  • What will the market size be in 2020 and what will the growth rate be?

  • What are the key market trends?

  • What is driving this market?

  • What are the challenges to market growth?

  • Who are the key vendors in this market space?

  • What are the market opportunities and threats faced by the key vendors?

  • What are the strengths and weaknesses of the key vendors?

Global Leukemia Therapeutics Market 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market
Market overview
Total addressable market for global CLL therapeutics
Vendors in the market

PART 09: Global ALL therapeutics market
Market overview
Vendors in the market

PART 10: Global AML therapeutics market
Market overview
Vendors in the market

PART 11: Global CML therapeutics market
Market overview
Vendors in the market

PART 12: Geographical segmentation
Global leukemia therapeutics market by geography 2015-2020
Leukemia therapeutics market in Americas
Leukemia therapeutics market in EMEA
Leukemia therapeutics market in APAC

PART 13: Market drivers
Special regulatory designations for drugs
Technological advances in the monitoring of leukemia
Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges
Complicated disease prognosis
Financial and infrastructural constraints
Limitations associated with current therapeutic options
Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends
Rise in the development of combination therapies
Patient assistance programs
Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape
Competitive scenario
Other prominent vendors

PART 19: Key vendor analysis
F. Hoffmann-La Roche
Novartis
Bristol-Myers Squibb
AbbVie
Teva Pharmaceuticals

PART 20: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Timeline of development of leukemia drugs
Exhibit 03: Impact of key customer segments on market 2015
Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015
Exhibit 05: Pipeline portfolio: Global CLL therapeutics market
Exhibit 06: Pipeline portfolio: Global CML therapeutics market
Exhibit 07: Pipeline portfolio: Global ALL therapeutics market
Exhibit 08: Pipeline portfolio: Global AML therapeutics market
Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 10: Distribution of people aged 60 years and over (millions)
Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions)
Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015
Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020
Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis
Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
Exhibit 19: Major vendors in the CLL therapeutics market 2015
Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions)
Exhibit 21: Major vendors in ALL therapeutics market 2015
Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions)
Exhibit 23: Major vendors in global AML therapeutics market
Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions)
Exhibit 25: Major vendors in global CML therapeutics market
Exhibit 26: Global leukemia therapeutics market by geography 2015-2020
Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020
Exhibit 28: Global share of leukemia therapeutics market by geography 2015
Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions)
Exhibit 30: Revenue/growth outlook in different countries/regions 2015
Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015
Exhibit 32: Leukemia therapeutics market in different regions by type of disease
Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas
Exhibit 34: Percentage share of new cases of leukemia in US 2014
Exhibit 35: Hispanic population percentage in US total population
Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA
Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC
Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 41: Orphan designation pipeline drugs for leukemia
Exhibit 42: Breakthrough therapy designation drugs for leukemia
Exhibit 43: Expanded indication approval drugs in the treatment of leukemia
Exhibit 44: Impact of drivers
Exhibit 45: Cost of therapy for some leukemia drugs
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Combination therapies under development for the treatment of leukemia
Exhibit 48: Leukemia drugs with patient assistance programs
Exhibit 49: Key vendors ranking 2015
Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015
Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020
Exhibit 52: F. Hoffmann-La Roche: Profile
Exhibit 53: F. Hoffmann-La Roche: Strength analysis
Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix
Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions)
Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015
Exhibit 58: Novartis: Profile
Exhibit 59: Novartis: Strength analysis
Exhibit 60: Novartis: Growth strategy matrix
Exhibit 61: Novartis: Opportunity assessment
Exhibit 62: Bristol-Myers Squibb: Profile
Exhibit 63: Bristol-Myers Squibb: Strength analysis
Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix
Exhibit 65: Bristol-Myers Squibb: Opportunity assessment
Exhibit 66: AbbVie: Profile
Exhibit 67: AbbVie: Strength analysis
Exhibit 68: AbbVie: Growth strategy matrix
Exhibit 69: AbbVie: Opportunity assessment
Exhibit 70: Teva Pharmaceuticals: Profile
Exhibit 71: Teva Pharmaceuticals: Strength analysis
Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix
Exhibit 73: Teva Pharmaceuticals: Opportunity assessment
Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • Epithelial Ovarian Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 507
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, p......
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 463
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resis......
  • Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 108
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsen......
  • Follicular Lymphoma - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 540
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Follicular Lymphoma - Pipeline Review, H2 2016, provides an overview of the Follicular Lymphoma (Oncology) pipeline landscape.Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargeme......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs